Ketamine tops our patent tracker by raw count: 71 granted, 117 pending — more than psilocybin (60/163), more than 5-MeO-DMT (52/112), more than anything else we track. By that measure alone, it should be the most contested, most fought-over compound in the psychedelic-adjacent space. It isn't. Ketamine is also the only compound here that's already legal, already prescribed, already generating real hospital revenue — and it's still not attracting anywhere near the speculative capital or company count that psilocybin and MDMA are pulling in from a standing start. The patent count is the clue to why.
Ketamine's public profile right now is split in two, and neither half is really about depression. Audiences know it as ordinary emergency-department medicine — a sedative and pain reliever used constantly in shows like The Pitt, which has built its reputation partly on getting real ER practice right. And they know it as the drug in Matthew Perry's 2023 death: the DEA and DOJ charged five people, including two doctors, over the ketamine that killed him, after DEA Administrator Anne Milgram said Perry had become addicted following ketamine treatments he'd received for depression and anxiety at a clinic. Both doctors have since surrendered their medical licenses. That case is a big part of why ketamine clinics are under more scrutiny now than at any point since esketamine's 2019 approval — real, warranted scrutiny that psilocybin and MDMA, still pre-approval, haven't had to face yet. We're also covering the supply side this week: UK Border Force seized 1,300kg of ketamine in just the first three months of 2026, on pace to blow past the prior full-year record.
Who Actually Holds the Patents
| Company | Granted | Pending | Notes |
|---|---|---|---|
| Janssen Pharmaceutica (J&J) | 2 | 11 | The Spravato (esketamine) franchise |
| Amorsa Therapeutics | 7 | 8 | Private |
| West Virginia University | 4 | 6 | Academic |
| National University Corporation | 3 | 5 | Academic |
| XWPharma / XW Laboratories | 3 + 2 | 2 + 3 | Split across two related entities |
| Develco Pharma Schweiz | 2 | 4 | — |
| Cooper Health System | 2 | 3 | — |
| SRI International / HHS | 2 (co-assigned) | 3 | Co-assigned with US HHS |
| Université de Liège | 2 | 2 | Academic |
That's roughly 31 of the 71 granted patents accounted for across nine holders — the rest sit in a long tail of single-patent filers and older inventor-held anesthesia-era patents, several already expired. Janssen's row is the one that matters most: only 2 granted patents, but that's the entire commercial foundation of Spravato, a drug that did $1.1 billion in 2025. Ketamine itself — the actual molecule — has been off-patent since the 1970s. Nobody can own it. J&J's workaround was to isolate and patent just the S-enantiomer (esketamine) and its delivery method, which is a real, defensible patent — but it protects a formulation, not the underlying pharmacology, and it's the only major commercial bet anyone's made on this compound.
Trials That Didn't Go as Planned
Janssen's own Phase 3 program for esketamine (the TRANSFORM/ASPIRE trials) wasn't a clean sweep: at least one late-stage study in elderly treatment-resistant depression narrowly missed its primary endpoint, and a separate trial testing esketamine plus an oral antidepressant against oral-antidepressant-plus-placebo failed to reach statistical significance at four weeks. J&J filed for approval anyway, on the strength of the trials that did work, which the FDA accepted — but it's not the unambiguous data package Spravato's reputation sometimes implies.
Since approval, the picture hasn't cleaned up. A 2026 systematic review and meta-analysis in the American Journal of Psychiatry found that randomized controlled ketamine/esketamine trials were "mostly negative or failed" at the 2–4 week mark, with only a weak overall effect size, and none of seven trials that measured suicidal ideation at four weeks came back positive, despite ketamine's reputation as a rapid antidote to suicidal crisis. A separate 2026 trial found repeated ketamine infusions failed to outperform an active placebo. And a review of industry-funded ketamine and esketamine trials registered on ClinicalTrials.gov between 2010 and 2022 found that 47% never published results at all — an unusually high silent-failure rate for a compound this widely used.
Why the Money's Going Elsewhere
None of this means ketamine doesn't work for some patients — it's genuinely, legally in use right now, which is more than psilocybin or MDMA can say. But it explains the investment gap. Psilocybin and MDMA are virgin patent territory: any company that files first on a specific crystalline form, salt, or delivery method gets real, novel intellectual property, which is exactly what's driving the 60-patent and growing land rush we covered in the psilocybin piece. Ketamine offers none of that upside. The molecule is public domain, the one workaround (esketamine) already has an owner, and the clinical data backing that owner's flagship product is more mixed than the "rapid-acting miracle drug" narrative suggests. There's no white space left to stake a claim on, and the closest thing to white space produced a program with real cracks in it — cracks that a high-profile overdose death has since made a lot more visible to regulators and the public.
The result is a compound that's ahead on access — approved, reimbursed in places, dispensed in ketamine clinics across the country right now — but behind on the kind of speculative, patent-driven momentum carrying psilocybin, MDMA, and ibogaine toward their own approvals, and now facing the kind of scrutiny that comes with real-world misuse rather than clinical-trial risk. It's a different path to relevance, not a failed one. Whether it's a better one is a separate question.
This is business and regulatory reporting, not medical advice. Spravato is FDA-approved for treatment-resistant depression in adults; other ketamine uses discussed here, including off-label IV ketamine, are not FDA-approved indications and carry real risks of dependence and misuse.
Sources
- Altitude Intelligence: Psychedelic Patent Tracker
- Altitude: Psilocybin Has 223 Patents in Play
- Altitude: UK Border Force Seized a Record 1,300kg of Ketamine
- DEA: Five Defendants, Including Two Doctors, Charged in Connection with Actor Matthew Perry's Fatal Overdose Death
- pharmaphorum: Mixed Phase 3 results from J&J's esketamine depression drug
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis — American Journal of Psychiatry
- Serial Ketamine Infusions Fail to Outperform Placebo in New Trial
- What the Ketamine Boom Could Mean for Pharma — Drug Discovery & Development